SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76941.61
105.83 (0.14%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Nephrocare Health Services Ltd.	Q V+ PT	6,853 Small Cap	688.45 (1.02%)	N/A	7.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Anthem Biosciences Ltd.	Q V PT	44,516 Mid Cap	780 (-1.28%)	71.31	13.68	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Krishna Institute of Medical Sciences Ltd	Q V PT	33,598 Small Cap	791.10 (-1.11%)	128.88	8.55	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Aster DM Quality Care Ltd.	Q V+ PT	70,000 Mid Cap	803.50 (0.06%)	180.35	14.2	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,009 Small Cap	821.70 (0.89%)	23.73	2.82	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Supriya Lifescience Ltd.	Q V+ PT	6,799 Small Cap	835.05 (-1.15%)	32.51	5.68	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Granules India Ltd.	Q V+ PT	20,878 Small Cap	843 (0.05%)	51.82	5.09	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,132 Small Cap	843.10 (-0.11%)	85.24	5.02	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Windlas Biotech Ltd.	Q V PT	1,769 Small Cap	858.60 (0.18%)	26.62	3.44	16.15	15.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Natco Pharma Ltd.	Q V PT	16,606 Small Cap	924.15 (-0.32%)	11.71	1.8	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Fortis Healthcare Ltd.	Q V+ PT	71,140 Mid Cap	943.40 (0.12%)	308.84	7.71	23.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Jubilant Pharmova Ltd.	Q V+ PT	15,582 Small Cap	960.25 (-1.84%)	783	6.74	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Innova Captab Ltd.	Q V PT	5,527 Small Cap	966.05 (0.02%)	66.04	6.23	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Orchid Pharma Ltd.	Q V PT	5,002 Small Cap	986.40 (0.01%)	110.65	3.65	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Strides Pharma Science Ltd.	Q V+ PT	9,623 Small Cap	1,055.20 (1.07%)	52.4	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Zydus Lifesciences Ltd.	Q V PT	1,10,523 Mid Cap	1,109.40 (0.13%)	21.93	4.25	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Max Healthcare Institute Ltd.	Q V PT	1,08,476 Mid Cap	1,114 (-0.05%)	75.2	10.23	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Alivus Life Sciences Ltd.	Q V PT	13,876 Small Cap	1,120.45 (-0.89%)	24.58	4.16	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Dr. Reddys Laboratories Ltd.	Q V+ PT	96,063 Mid Cap	1,144.90 (-0.52%)	29.81	2.52	12.09	15.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Concord Biotech Ltd.	Q V PT	13,150 Small Cap	1,252.25 (-0.38%)	50.4	6.52	11.33	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	3B Blackbio Dx Ltd.	Q V PT	1,112 Small Cap	1,290 (-0.39%)	22.54	4.07	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Sai Life Sciences Ltd.	Q V+ PT	27,347 Small Cap	1,293.50 (0.42%)	80.08	10.9	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Senores Pharmaceuticals Ltd.	Q V+ PT	6,500 Small Cap	1,318.70 (-6.57%)	349.68	8.67	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Vijaya Diagnostic Centre Ltd.	Q V PT	13,894 Small Cap	1,347 (-0.14%)	80.32	14.52	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Eris Lifesciences Ltd.	Q V PT	19,400 Small Cap	1,393.10 (-0.49%)	31.32	4.97	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Global Health Ltd.	Q V PT	37,844 Small Cap	1,405.80 (-0.12%)	76.27	9.41	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Cipla Ltd.	Q V PT	1,13,894 Large Cap	1,434.60 (1.76%)	33.79	3.24	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Rainbow Childrens Medicare Ltd.	Q V PT	15,076 Small Cap	1,471 (-0.90%)	60.3	8.95	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Aurobindo Pharma Ltd.	Q V+ PT	89,115 Mid Cap	1,551 (0.14%)	36.9	3.92	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Rubicon Research Ltd.	Q V+ PT	25,860 Small Cap	1,566.10 (0.25%)	137.43	19.11	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.25	3.23%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	592.35	2.53%
Fabtech Technologies	152.35	2.49%
Laurus Labs	1,745.85	1.84%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,109.85	-7.68%
Senores Pharmaceutic	1,318.70	-6.57%
Suven Life Sciences	298.90	-4.11%
Wanbury	318.45	-3.85%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Cipla gets USFDA’s approval for Generic Advair Diskus

The product is a therapeutically equivalent version of Advair Diskus, a widely prescribed combination therapy indicated for the treatment of asthma and COPD

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

Anthem Biosciences informs about transcript of conference call

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anthem Biosciences has informed that it enclosed the transcript of the earnings conference call held on July 22, 2026, at 11:30 AM, post announcement of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at https://anthembio.com/.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Consolidated total income of the company increased by 1.58% to Rs 7,330.18 crore in Q1FY27

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	202 Crore
2	Syncom Formulations (India) Ltd.	1,240 Crore
3	Sigachi Industries Ltd.	991 Crore
4	Fischer Medical Ventures Ltd.	2,464 Crore
5	Morepen Laboratories Ltd.	3,101 Crore
6	Anuh Pharma Ltd.	809 Crore
7	Themis Medicare Ltd.	995 Crore
8	Gujarat Kidney And Super Speciality Ltd.	1,004 Crore
9	KMC Speciality Hospitals (India) Ltd.	2,127 Crore
10	IOL Chemicals And Pharmaceuticals Ltd.	4,453 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,629	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,551	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,586	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,145	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,983	4,73,509	41.25	5.67	23.65	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Cipla gets USFDA’s approval for Generic Advair Diskus

Senores Pharmaceutic - Quaterly Results

Anthem Biosciences informs about transcript of conference call

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Cipla surges despite reporting 39% fall in Q1 consolidated net profit

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.